Hoechst and Rhone-Poulenc deal
HOECHST SHAREHOLDERS yesterday overwhelmingly backed the $22bn merger of Germany's largest drugmaker with France's Rhone-Poulenc, paving the way for the creation of the joint company before the end of the year. The vote concludes a 20-hour meeting over two days, one of the longest in German corporate history. Jurgen Dormann, chief executive (left), told shareholders that Celanese, the company formed from Hoechst's industrial- chemicals businesses scheduled to be spun off in October, would cut 1,000 jobs. Both Hoechst and Rhone-Poulenc are moving away from chemicals to focus on more profitable pharmaceuticals and agrochemicals.
The merged company will have more than $20bn in annual sales and will leapfrog AstraZeneca - the product of a $40bn merger completed earlier this year - as the biggest company in the global pharmaceuticals market.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies